Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kazia Therapeutics Limited (KZIA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.66-0.12 (-1.11%)
At close: 4:00PM EDT
Advertisement

Kazia Therapeutics Limited

Three International Towers
Level 24 300 Barangaroo Avenue
Sydney, NSW 2000
Australia

http://www.kaziatherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (CEO, MD & Exec. Director674.64kN/A1973
Ms. Gabrielle HeatonDirector of Fin. & Admin.186.96kN/AN/A
Ms. Catherine Jane Hill B.Sc., C.A., ACA, GAICD, BSc (Hons)Company Sec.100.69kN/A1960
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Corporate Governance

Kazia Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement